Clinical trials: Oral Stage
Carcinoma, Hepatocellular
Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
To compare the overall survival of thalidomide- and placebo-treated advanced HCC patients.
- Trial name
- NCT00225290
- Testing
- Thalidomide(Thado)
- Where
- Taiwan
- Volunteers
- 230 people
- Sponsor
- TTY Biopharm
Secondary Hyperparathyroidism, End Stage Renal Disease
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients
This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.
- Trial name
- NCT00037635
- Testing
- AMG 073
- Volunteers
- 400 people
- Sponsor
- Amgen
Multiple Myeloma
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma
The primary purpose of this dose escalation study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) of LGH447 as a single agent when administered orally once daily to adult patients with…
- Trial name
- NCT01456689
- Testing
- LGH447, midazolam
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Cancer Pain
IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration
Based on the previous HMORCT09-2, the results show that IV PCA for analgesia maintenance improvements control of severe cancer pain after successful titration.
- Trial name
- NCT04785768
- Testing
- Hydromorphone Hydrochloride Injection, Morphine Sulfate Sustained-release Tablets
- Where
- China
- Volunteers
- 1,372 people
- Sponsor
- Fujian Cancer Hospital
Advanced Solid Tumors
A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.
This study assesses the tolerability, safety, efficacy and pharmacokinetics of gimatecan in Japanese patients. Gimatecan is administered orally for five consecutive days, every 28 days, to adult patients with advanced solid…
- Trial name
- NCT00410358
- Testing
- Gimatecan
- Where
- Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel
Investigate the effect of multiple oral doses of BI 207127 + faldaprevir (FDV) on the multiple dose pharmacokinetics of ethinylestradiol and levonorgestrel (Microgynon®) in healthy premenopausal female volunteers.
- Trial name
- NCT01941615
- Testing
- faldaprevir, Microgynon®, BI 207127
- Where
- Germany
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Malignant Tumor of Head and/or Neck, Radiotherapy; Complications
Acupuncture for Prevention and Treatment of Oral-related Complications Caused by Radiotherapy for Head and Neck Cancer
A study on the efficacy and safety of acupuncture for the prevention and treatment of oral-related complications caused by radiotherapy for head and neck malignant tumors
- Trial name
- NCT06272617
- Testing
- verum acupuncture
- Where
- China
- Volunteers
- 138 people
- Sponsor
- West China Hospital
Diabetes Mellitus, Type 2
A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus
Randomized, placebo-controlled, parallel-group, double-blind, multiple-dose, activity and safety clinical study of SRT2104 administered orally once daily for 28 consecutive days.
- Trial name
- NCT01018017
- Testing
- SRT2104
- Where
- Germany
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Anemia, Dialysis-Dependent Chronic Kidney Disease
Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction or maintenance treatment of anemia in participants with incident dialysis-dependent chronic kidney disease (DD-CKD).
- Trial name
- NCT02865850
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 118 sites in United States, Argentina and 9 more
- Volunteers
- 369 people
- Sponsor
- Akebia Therapeutics
Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
A phase 1/2, first-in-human, open-label study to determine the safety, tolerability, PK, and preliminary efficacy of the novel RET/SRC inhibitor TPX-0046 in adult subjects with advanced or metastatic solid tumors harboring RET…
- Conditions
- Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET Gene Mutation, Metastatic Solid Tumor
- Trial name
- NCT04161391
- Testing
- TPX-0046
- Where
- 21 sites in United States, South Korea
- Volunteers
- 41 people
- Sponsor
- Turning Point Therapeutics, Inc.
Healthy
A Study Comparing the Bioavailability of a Taste-masked Delafloxacin Powder for Oral Suspension With the Delafloxacin Tablet in Healthy Adults
This study will compare the bioavailability of a novel powder for oral suspension formulation of delafloxacin, intended for treatment of community acquired bacterial pneumonia, to that of the licensed delafloxacin oral tablet in…
- Trial name
- NCT06612255
- Testing
- Delafloxacin, Delafloxacin Powder
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Melinta Therapeutics, Inc.
Healthy
To Evaluate the PK, PD, Safety and Drug Tolerance of JW0302 in Healthy Volunteers
1. To evaluate the pharmacokinetic and pharmacodynamics characteristics after administration of Reference Drug or Test Drug in healthy volunteers under fasting conditions 2.
- Trial name
- NCT05784155
- Testing
- Test Drug(JW0302) or Reference Drug(C2206)
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- JW Pharmaceutical
High-grade Glioma, Oligodendroglioma
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
This is a phase 1 open-label, multicenter study to investigate tolerability, safety and PK properties of oral OKN-007 in patients with recurrent high-grade glioma.
- Conditions
- High-grade Glioma, Oligodendroglioma, Astrocytoma, Glioblastoma Multiforme
- Trial name
- NCT05561374
- Testing
- Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Oblato, Inc.
Type 2 Diabetes Patients
A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in…
- Trial name
- NCT01298518
- Testing
- PF-04620110
- Where
- 3 sites in United States
- Volunteers
- 48 people
- Sponsor
- Pfizer
Neoplasms
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of the combination of BI 6727 with BIBW 2992, in patients with advanced or metastatic solid…
- Trial name
- NCT01206816
- Testing
- BI 6727 + BIBW 2992
- Where
- 3 sites in Belgium
- Volunteers
- 57 people
- Sponsor
- Boehringer Ingelheim
Atopic Dermatitis
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
This is a study to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult male and female patients with moderate to severe atopic dermatitis (AD).
- Trial name
- BroADen (NCT06945458)
- Testing
- KT-621
- Where
- 12 sites in United States
- Volunteers
- 22 people
- Sponsor
- Kymera Therapeutics, Inc.
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Healthy
A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants
The main purpose of this study is to conduct blood tests to measure how much pirtobrutinib (LOXO-305) is in the bloodstream and how the body handles and eliminates pirtobrutinib (LOXO-305) after meals and on an empty stomach.
- Trial name
- NCT06180980
- Testing
- Pirtobrutinib
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Drug Toxicity
Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects
To Evaluate the safety and tolerability after KD101 single oral dosing in healthy male subjects To Evaluate the pharmacokinetic property after KD101 single oral dosing in healthy male subjects To Evaluate the effect of food on…
- Trial name
- NCT01979380
- Testing
- KD101
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Pain
Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066
The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.
- Trial name
- NCT00829088
- Testing
- AZD2066
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca